IP Library Granted Patent US 8,481,715
Granted Patent B2
US 8,481,715 · App. 13/489,307 · Granted Jul 9, 2013

Methods for isolating crystalline form I of 5-azacytidine

Inventors: Dumitru Ionescu (Ann Arbor, MI); Peter Blumbergs (Royal Oak, MI); Gary L. Silvey (Overland Park, KS)
Assignee: Pharmion LLC
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,481,715
App. No.
13/489,307
Granted
Jul 9, 2013
Kind
B2
Abstract

The invention includes methods for isolating crystalline Form I of 5-azacytidine substantially free of other forms, wherein 5-azacytidine is represented by the formula: The invention also includes pharmaceutical compositions comprising Form I of 5-azacytidine.

Claims (56)

1. A method for isolating crystalline Form I of 5-azacytidine substantially free of other forms, the method comprising:

recrystallizing 5-azacytidine from a solvent mixture comprising at least one polar aprotic solvent and at least one co-solvent selected from the group consisting of:

1,1,2-trichloroethene,

1,2-dichloroethene,

1,2-dimethoxyethane,

1,4-dioxane,

1-butanol,

1-pentanol,

1-propanol,

2-butanol,

2-ethoxyethanol,

2-methoxyethanol,

2-methyl-1-propanol,

2-propanol,

3-methyl-1-butanol,

acetone,

acetonitrile,

anisole,

butyl acetate,

chlorobenzene,

cumene,

cyclohexane,

dichloromethane,

ethyl acetate,

ethyl ether,

ethyl formate,

ethyleneglycol,

formamide,

isobutyl acetate,

isopropyl acetate,

methyl acetate,

methylbutyl ketone,

methylcyclohexane,

methylisobutyl ketone,

N,N-dimethylacetamide,

N,N-dimethylformamide,

nitromethane,

propyl acetate,

pyridine,

sulfolane,

tert-butylmethyl ether,

tetrahydrofuran, and

tetralin,

by cooling the solvent mixture from a temperature at which the 5-azacytidine dissolves completely to about −20° C.; and

isolating the recrystallized 5-azacytidine.

2. The method of claim 1 , wherein said polar aprotic solvent is selected from the group consisting of dimethylsulfoxide, dimethylformamide, dimethylacetamide, and N-methylpyrrolidinone.

3. The method of claim 1 , wherein said polar aprotic solvent is dimethylsulfoxide.

4. The method of claim 1 , wherein said co-solvent is acetonitrile.

5. The method of claim 1 , wherein said co-solvent is 2-propanol.

6. The method of claim 1 , wherein said co-solvent is 1-propanol.

7. The method of claim 2 , wherein said co-solvent is acetonitrile.

8. The method of claim 2 , wherein said co-solvent is 2-propanol.

9. The method of claim 2 , wherein said co-solvent is 1-propanol.

10. The method of claim 3 , wherein said co-solvent is acetonitrile.

11. The method of claim 3 , wherein said co-solvent is 2-propanol.

12. The method of claim 3 , wherein said co-solvent is 1-propanol.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2012
From: SILVEY, GARY L.
To: PHARMION CORPORATION
Reel/Frame 028327/0792 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2012
From: IONESCU, DUMITRU; BLUMBERGS, PETER
To: ASH STEVENS, INC.
Reel/Frame 028327/0807 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2012
From: ASH STEVENS, INC.
To: CELGENE INTERNATIONAL SARL
Reel/Frame 028327/0843 →
MERGER Recorded Jun 6, 2012
From: PHARMION CORPORATION
To: PHARMION LLC
Reel/Frame 028327/0863 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2012
From: CELGENE INTERNATIONAL SARL
To: PHARMION LLC
Reel/Frame 028327/0960 →
Continuity (4)
Division 12729116 · Mar 22, 2010
Continuation 11198550 · Aug 5, 2005
Division 10390530 · Mar 17, 2003
Related Publication 20120245342A1 · Sep 27, 2012